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Abstract 
  Health care costs particularly those associated with chronic health conditions such 
as cancer have been significantly increasing for both individuals and governments in the 
past decades, prompting the demand for preventative medical initiatives, such as 
functional food, and spawning a new industry in the food sector – functional food 
industry.  This article conducts a feasibility study for a firm entering the functional food 
industry with a specific product, Avert
®, CLA-enhanced cheese.  It also assesses 
alternative market conditions under which the firm will be successful.  A system 
dynamics framework is used for the analyses.  The results show that a firm can be 
profitable in the functional food industry provided that it satisfies certain pricing and 
target market conditions.  The results indicate that the extent to which the market 
differentiates Avert
® from commodity cheese, and hence the premium it pays, is a critical 
success factor for the firm introducing the product.   With improved scientific knowledge and technology, people are living longer with more 
diseases and disabilities than ever before and consequently, taxing the health care system.  
Functional foods are being considered as a ‘magic food’ to alleviate some of the health care 
costs associated with aging. Innovative food products are being developed to minimize the 
incidence and extent of illnesses and diseases in particular chronic health problems, thereby 
enhancing the quality of life especially as people age.  Recently, the discoveries of new food 
components (e.g., phytochemicals) that do not contribute to basic nutrition but may prevent 
disease have presented a new dimension to the functionality of food.  These foods are 
referred to as functional foods– foods that provide additional physiological benefits beyond 
meeting basic nutritional needs (Hasler, 2002).  
  US health care costs have been increasing at a dramatic rate over the past decade.  A 
large majority of US health care costs is spent on treating illnesses associated with aging 
societies such as cancer. Cancer is the second leading cause of death in the US and is 
responsible for 25 percent of all deaths in the US.   From the Cancer Statistics 2006 report, an 
estimated 564, 830 Americans will die from cancer in 2006 (ACS, 2006).  When the deaths 
are aggregated by age, cancer has replaced CVD as the leading cause of death among 
Americans under 85 years of age (Jemal et al., 2005).  The most prevalent cancers affecting 
aging societies are skin, lung, and hormone-dependent (e.g., breast and prostate) (CDC, 
2004c).  
  While age and genetics play a role, approximately 50 to 75 percent of all cancers are 
lifestyle related and thus, preventable (National Cancer Institute, 2004).  An individual can 
reduce their risk for cancer by achieving optimal health through avoiding tobacco use, being 
physically active, reducing sun exposure, and consuming a proper diet (ACS, 2004; WHO, 
  32005).  According to the Cancer Research UK (2004), one-third of all cancers are linked to 
diet.   
  The total cost of cancer, including direct and indirect costs, in the US estimated by 
the National Institutes of Health in 2002 was $171.6 billion.  An additional $3 to $4 billion 
from cancer screening test (e.g., mammograms) is added to the total cost.  More than one half 
of the direct medical costs associated with cancer are attributed to breast ($6 billion), lung 
($5 billion), and prostate ($5 billion) cancer treatments (ASCEND, 2003).   
  Improved quality of life and chronic health problems have become a major focus in 
functional foods research.  There is an overwhelming amount of scientific evidence to 
support the protective effects of plant and animal sources against chronic health problems in 
particular certain types of cancer.  Recent research has discovered many beneficial 
components in dairy products in particular conjugated linoleic acid (CLA).  CLA is a 
naturally occurring fatty acid in rumen animals and its quantity in food products can be 
enhanced by feeding animals a specialized diet.  Numerous scientific studies indicate that 
CLA has antiatherogenic, antidiabetic, antiobesity, and positive immune effects.  However, 
the majority of the research supports CLA’s anticarcinogenic properties. 
  Functional foods have the potential to provide significant health benefits that would 
result in reducing health care costs.  By developing functional food products, the consumer 
could gain from both the resulting health benefits and the lower costs associated with health 
care and customized food products.  However, these products will only be developed if 
innovative food firms manufacturing these products can maximize their profit.  In other 
words, these firms must be able to generate revenue higher than the high cost associated with 
the development and regulation of functional food products. Therefore, this research seeks to 
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industry?  The secondary question asks the following: Under which conditions will a firm by 
profitable? 
  The article will review the scientific, business, and economic literature pertaining to 
the health benefits of CLA-enhanced food products with respect to cancer, evaluating the 
efficacy of CLA-enhanced food products in controlling chronic health problems.  Specific 
product and market conditions needed for the firm to be successful will be identified.  A 
system dynamic model will be developed to investigate the economic feasibility of 
introducing a CLA-enhanced food product provided that the conditions hold.  A discussion of 
the results of the profits earned from the different scenarios will be presented.  Finally, a 
conclusion along with recommendations for future research is presented.   
CLA and Health Benefits   
CLA is present in milk fat and adipose tissue
1 of ruminants.  It refers to a group of 
polyunsaturated fatty acids derived from linoleic acid, which is isomerized by a rumen 
microorganism, Butyrivibrio fibrisolvens, to produce the transient intermediate CLA.  Further 
reduction of CLA forms trans-11 octadecenoic acid (trans11-18:1 or vaccenic acid) and 
stearic acid.   Interestingly, polyunsaturated fatty acids (e.g., linolenic acid obtained from 
pasture feeding, fish oil and linolenic oil feeding) through a number of biochemical reactions 
can be re-synthesized into cis-9, trans-11-CLA by delta-9-desaturase in the mammary gland 
and adipocytes.  In fact, endogenous synthesis of CLA by delta-9-desaturase represents the 
major source of CLA in milk fat of lactating cows (Griinari et al, 2000).  
 The  cis-9, trans-11-CLA isomer is the most naturally abundant form of CLA and 
contributes 85 to 90 percent of milk fat total CLA (Tricon et al., 2004).  The other bioactive 
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to have antitumor and antiatherogenic effects whereas trans-10, cis12-CLA is thought to 
have antiobese and antidiabetic effects.    
  CLA has been found to be an anticancer agent at multiple stages of cancer 
development (i.e., initiation, promotion, progression, and metastasis) in multiple organ 
systems in the body (e.g., breast, prostate, skin, and colon).   Mechanisms by which CLA’s 
exerts its anticarcinogenic effects are by modulating free radical-induced oxidation, 
carcinogen metabolism and carcinogen-DNA adduct formation in the skin and other tissues.   
Consumption of synthetic CLA (consisting of relatively equal amounts of cis-9, trans-11-
CLA and trans-10, cis-12-CLA) during or after the initiation stage of cancer development 
has been found to delay or reduce the onset of chemically induced skin tumor promotion or 
mammary and colon tumorigenesis (Belury, 2002).  
  The effects of CLA on post-initiation cancer development include its ability to reduce 
growth rates of mammary and prostate cancer cells implanted in vivo in mice.  In one study, 
Hubbard et al. (2000) investigated the effect of CLA on the latency, metastasis and 
pulmonary tumor burden
2 in mice fed a 20 percent fat diet including CLA content ranging 
for zero to one percent.  The mice fed the CLA diets experienced an increase in the latency of 
tumors compared to the group of mice not fed CLA.  Results also suggest an inverse 
relationship between the amount of CLA in the diet and the volume of pulmonary tumor 
burden decreased.   These findings suggest that CLA may have a positive effect on tumor 
incidence in the later stages of breast cancer (i.e., metastasis). 
  Another anticarcinogenic mechanism used by CLA is its ability to modulate cell 
proliferation
3 and apoptosis (programmed cell death).  Palombo et al. (2002) studied the 
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and  trans-10,cis12-CLA) using human colorectal and prostate carcinoma cells.  Results of 
the study revealed that both CLA isomers had moderate effects against prostate cancer.  In 
addition, trans-10, cis12-CLA isomer possessed the greatest potency against colorectal 
cancer and induced apoptosis in the colorectal and prostate cancer cells.  These findings 
suggest that commercial prepared CLA may be an effective chemopreventive agent.  
  Other studies have determined that CLA induces apoptosis in mammary gland, liver, 
colon and adipose tissues by reducing levels of proteins (i.e., Bcl-2) that suppress apoptosis 
(Park et al., 2004; Belury, 2002).   Studies have also suggested that CLA’s effects on 
apoptosis may be attributed to CLA’s effect on arachidonic acid metabolism.   CLA has the 
ability to reduce the formation of eicosanoids, a class of lipids metabolites derived from 
arachidonic acid as well as decrease the metabolism of phospholipids fatty acids. This is a 
particularly important finding since eicosanoids modulate tumorigenesis in the mammary 
gland, skin, prostate and colon (Belury, 2002).   
  Although scientific evidence strongly supports CLA’s ability to inhibit cancer 
development, a few studies contradict these results.  CLA is thought to inhibit the growth of 
transplantation of cell lines from mammary and prostate.  However, Hansen Petrik et al. 
(2000) discovered that CLA did not exert antitumorgenic effects.  In the study, the 
antitumorgenic effects of CLA on Apc
Min/+ mouse (a useful model to study early intestinal 
tumorigenesis) and the changes in prostaglandin biosynthesis were examined.  Results from 
the study revealed that the amount of CLA was not effective at the set dosage to inhibit 
tumorgenesis nor did it significantly affect prostaglandin levels. It is important to note that no 
research has discovered that CLA promotes tumorgenesis (Belury, 2002).   
  7CLA Enhancement in Dairy Products 
  The CLA content in dairy products can be greatly increased by appropriate genetic 
selection, and a specialty diet but post-harvesting factors in the processing of dairy products 
(e.g., pasteurizating and aging) has little to no effect (Bauman et al., 2005).  Individual 
variation in cattle within a herd can account for a two to three fold variation in CLA content 
in milk fat (Kelly et al., 1998a, 1998b; Lock and Garnsworthy, 2002, 2003).  Kelsey et al. 
(2003) and Bauman et al. (2005) suggest that the majority of the differences in CLA content 
in milk fat among cows can be attributed to individual variation in delta-9-desaturase gene 
expression and the rumen outflow of VA and CLA.  This difference may be attributed to 
genetic variation among the cows.    
  By placing the cow on a specific diet, farmers can alter the CLA content present in 
milk fat.  Ruminants that graze on pastures have five times higher CLA content in their milk 
than ruminants fed a diet consisting of 50 percent forage (e.g., alfalfa and corn silage) and 50 
percent grain (Harris, 2001; Robinson, 2002).  Interestingly, dry feed diets comprised of two 
to four percent soybean and linseed (flaxseed) oil are found to produced CLA levels that 
were similar to levels found in pasture fed cattle (Harris, 2001).  However, diets with high oil 
percentage can adversely affect the digestibility of the feed and metabolism of rumen 
bacteria (Jenkins, 1993; Harris, 2001).   
  Since the majority of CLA is suggested to be endogenously synthesized by delta-9-
desaturase, the most economical method to enhance CLA in milk fat may be to allow cattle 
to graze on green growing pastures, feed cows supplements containing trans-11-18:1 or 
management of rumen biohydrogenation through a special diet to increase the formation and 
accumulation of trans-11-18:1 (Griinari et al., 2000).  It is important to note, that a pasture 
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content and possibly fat content (Khanal and Olson, 2004; Jones et al., 2005, Bauman and 
Griinari, 2003; Chouinard et al., 2001).  Given that producers receive a milk price for each 
pound of milk component markets or the amount of milk components present per 
hundredweight of milk
4, milk producers should be financially compensated for the revenue 
lost from the reduction in milk yield and milk fat content experienced from producing CLA-
enhanced milk.  This implies that there is some level of CLA that would optimize milk 
production and lead to the highest economic benefit to dairy producers. 
Market Potential for CLA-Enhanced Food Products 
Numerous studies have investigated the health and market potential for CLA-enhanced dairy 
products.  Parodi (2003) suggests that the “effective CLA” from the effective CLA intake is 
140 to 420 mg/d which is within two to five-fold range of the estimated CLA intake needed 
to provide a health benefit.  Findings from two different sensory studies by Lynch et al. 
(2005) and Jones et al., (2005) suggest that CLA-enhanced dairy products are not more 
susceptible to developing off-flavors from oxidation than the control milk even when 
oxidation was induced by light exposure and no off flavors were detected by untrained taste 
testers. 
  Functional foods are considered innovative new products.  Innovation is defined as 
the development of something new or someone perceives the products as being new and it is 
believed to be the essence of economics in particular modern economics (Amanor-Boadu, 
2005). Innovations change the characteristics of the market by using existing resources to 
create new products and services, developing new processes and products, and/or 
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preferences are considered to be driving forces behind innovation (Mark-Herbert, 2002). 
  The successful introduction of a new product to the marketplace requires effective 
pricing, advertising and other marketing programs.  Choosing the product’s selling price is 
one of the most important yet difficult decisions.  The pricing objective of CLA-enhanced 
milk products is to attract new customers based on perceived health benefits; therefore firms 
should employ a premium pricing program. 
Profile for Functional Food Consumers   
Consumers have become increasing aware of the risk of certain health conditions as well as 
the risk associated with certain foods.  Well informed consumers are seeking healthy 
alternatives to these unhealthy diets as well as proactive alternatives to decrease the risk of 
these health conditions.  Functional foods present a unique solution to meet consumers’ 
needs.  However, the demand for functional foods is dependent on consumer’s perception of 
health risks and their willingness to change their food habits and willingness to pay for a 
healthier product.   
  In general, women are more likely than men to be concerned about the health benefits 
associated with foods.  Income and education are socio-demographic variables that are 
positively related to the belief in functional foods and their health benefits.  Consumers aged 
35-64 ages are more likely to believe in the health benefits of functional foods than 
consumers younger or older than this age group (Plaami, 2001, IFIC, 2005).   
  Another important aspect to the success of functional foods is the health claim or 
health message that is associated with the product.  Consumers are more likely to understand 
and trust a health claim/message that is coupled with a brand name product (e.g., Becel Pro-
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functional food product lines.  Interestingly, the majority of consumers are responsive to 
“soft” health message such as “for a better heart” or “your stomach will thank you”.  
Therefore, even though, scientific approval of a health product is needed to achieve a health 
claim for the product, scientific language is not needed to market the health product (Mark-
Herbert, 2002). 
Specific Conditions for Success 
Thus far, we have reviewed the scientific literature and we have discovered that there is 
potential for a CLA-enhanced food product to help prevent certain cancers.  We indicated it 
is possible to achieve such a product by feeding the dairy cows a specialty diet.  Also, we 
have determined the profile of a functional food consumer.  With these factors in mind, a 
firm will not introduce such a product unless there is a profit to be made.  In order for a firm 
to be successful, specific product and market conditions must hold.    
Condition One:   The CLA-enhanced product must be priced appropriately with respect to its 
alternatives.  
Even though, there are no set rules to determine the correct selling price, it is common 
practice to have a pricing strategy that is consistent with their marketing strategy.    There are 
two main types of marketing strategies: primary-demand strategies and selective-demand 
strategies.  Primary-demand strategies are associated with increasing the number of users or 
increasing the rate of purchase.  In both cases, lowering the price may be able to achieve the 
desired strategy (Guiltinan et al., 1997). 
  The effectiveness of pricing programs in the selective-demand strategies is dependent 
on the value of the cross price elasticities between the different products.  In the case of a 
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must take into consideration the cross price elasticities between the existing products and the 
new products.  If the cross price elasticity is positive, the probability of cannibalization of 
existing product sales is high.  Moreover, if the cross price elasticity is positive and the new 
product is considered to be of “higher quality” than existing products, then a high price 
associated with the new product would signify the product’s higher quality (Guiltinan et al., 
1997). 
  Premium pricing refers to a price set above competitive levels.  This pricing approach 
is successful if a firm can position its product on the inelastic company-demand curve either 
by differentiating the product in terms of higher quality, superior features or special services.  
Premium pricing can result in higher contribution margins as well as protection from price 
competition.    The following are conditions that favor a premium pricing program: inelastic 
company demand; no excess capacity by the firm; strong barriers to entry; minor gains to 
economies of scale; and new customers are attracted by product quality (Guiltinan et al., 
1997).  The latter condition can be applied to the CLA enhanced milk product industry. The 
pricing objective of CLA-enhanced milk products is to attract new customers based on 
perceived health benefits; therefore firms should employ a premium pricing program.  In 
order to gain the most revenue, firms should set the premium price so that its cross price 
elasticity is positive with respect to existing milk products.  Therefore, consumers view the 
product as being a high quality substitute to existing milk products.  
  It is also important to price the CLA-enhanced milk product below pharmaceutical 
drugs that are designed to help treat and/or prevent certain types of cancers. It is likely that 
rational individuals would rather spend a portion of their income on less expensive 
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improve their health.  Since the firm is offering a lower priced food product that is of the 
same quality as expensive pharmaceutical drugs, which only a limited portion of the 
population can afford, more people will be willing to purchase the food product than the 
pharmaceutical drugs.  Thus, the firm is able to gain a profit by receiving a fraction of the 
income that would have been spent on the pharmaceutical drugs because of the firm’s 
consumer market.        
Condition 2:  Appropriate Target Market 
  According to Mark-Herbert and Nyström (2000), there are four market segments with 
different needs for functional foods.  The largest segment is the “mass market” which refers 
to the average consumer who have no to little interest in functional foods.  The next segment 
is the “prevention” segment.  This segment consists of health conscious consumers who are 
interested in how foods and physical activity can affect their health.  Consumers that are 
aware of a risk of developing a certain health condition (i.e., hereditary breast cancer) are 
more likely to change their diet and lifestyle to decrease their risk.  These consumers 
represent the “at risk” segment.  The final and smallest market segment is the “suffers” which 
consists of the consumers who have symptoms of a health condition and have the highest 
motivation to try a new health related product.   
  Since there is no direct cure for cancer, cancer prevention is of utmost importance 
especially among the population that considers itself at risk.  Therefore, a proactive approach 
against the development of cancer is vital in maintaining a population’s positive health status.  
This preventative market (includes the At Risk and Prevention market segments) is 
considered to be the best market for the CLA-enhanced food product.  Within the 
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consumer profile.   
  Firms will only enter into the functional food industry out of self interest to maximize 
their profits and not to serve for the “public good”.  Before a firm enters into the functional 
food industry, it must first determine the potential for profits, evaluate the costs involved, and 
develop a plan for distributing the profit between itself and others involved in the production 
process (i.e., laborers).  Even though there is potential for large profits to be gained in the 
functional food and nutraceutical industry, the costs of developing, manufacturing, and 
marketing these customized food products may be high and could possibly outweigh the 
profits. Firms also must take into account the possible lengthy and costly regulation 
procedures that manufacturers must engage in to verify the safety and efficacy of the product 
before the product can be marketed.  Thus, firms need to evaluate the cost-benefit ratio 
involved in entering into this new industry.   
  Given that there is a relatively new market area and that there is little information 
pertaining to the firms developing and introducing a CLA-enhanced food product to market, 
we must create a hypothetical case study to investigate our research questions.  We have 
created a hypothetical firm, Healthy Dairy and we are using dynamic modeling techniques to 
conduct a feasibility study for Healthy Dairy entering into the functional food industry.  
  
Method 
Dynamic models allow for examination of supply chain responses to changes in the external 
environment.  Continuum, dynamic models that are used to study supply chains are based on 
the System Dynamics (SD) methodology developed by Jay Forrester.  SD is an 
interdisciplinary analytical tool which models the interrelatedness of system forces using the 
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counteract one another (Senge, 1990).  Due to the nonlinear complexity of supply chains as 
well as the feedback among the partners in the supply chain, SD methodology is a useful tool 
to model and analysis the behavior of supply chains (Carlevaro et al., 2004).  Stella
® is the 
computer program used in this study.    
    SD is fundamentally different from empirical approaches such as historical analysis, 
optimization analysis, and econometrics.  Unlike these traditional approaches, data collection 
does not play a dominant role in SD models.  This is one of the primary reasons why SD was 
chosen as the modeling program used in this article.  Despite the lack of historical data 
associated with this research topic, SD is able to adequately model the socio-economic 
relationships involved in this research thesis topic.   
  SD is a scenario analysis tool not an optimization tool and it is driven by assumptions.  
The modeler is forced to specify the assumptions in order to gain a better understanding of 
the world.  SD projects how the future world would behave under different scenarios.  Thus, 
it does not choose the optimal result but presents various scenarios of what the future may 
look like. 
  In this article, SD methodology has been used to study a specific agri-food chain in 
order to describe its operation.  The agri-food chain under investigation is the functional food 
industry - more specifically CLA-enhanced cheese - in the United States.  Cheese was chosen 
as the dairy product because CLA is a fatty acid and it can be effectively enhanced in high fat 
milk products.  Also, the cheese industry was chosen due to the fact that American cheese 
consumption has doubled since 1975.  According to ACNielsen, total cheese sales for the 
year ending April 16, 2005, were $9.2 billion in food, drug, and mass merchandising stores, 
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5  In 2004, 
the per capita consumption of cheese was approximately 31 pounds (ERS, 2004).  Therefore, 
cheese is an ideal food product because of it high fat content and its increase in popularity 
with American consumers. 
Model 
In order to develop a model that represents the complexity of the real world, assumptions are 
needed.  These assumptions are critical in (1) creating an abstraction from reality that is as 
close to reality as possible and (2) increasing our understanding of the relationships of the 
real world as much as possible. 
  As previously mentioned, Healthy Dairy is a hypothetical dairy product manufacturer 
with keen interest in developing a supply chain to bring Avert
®, a CLA-enhanced cheese to 
market.  Avert
® is a versatile product and its regular consumption that is known to improve a 
human’s health status by reducing the incidence and/or improving the symptoms of cancer.  
Presently, Healthy Dairy manufactures traditional cheese and skim milk powder at one 
processing facility strategically located in the South Central Valley in California close to 
milk producers.  Currently, Healthy Dairy has approximately 0.004 percent of the market 
share.  This implies that Healthy Dairy does not have market power to change or shift the 
market or its prices.   
  In producing Avert
®, Healthy Dairy requires its milk suppliers to produce CLA-
enhanced milk.  For this, Healthy Dairy is willing to pay a premium based on the 
concentration level of CLA in the milk.  To help producers achieve the level of CLA 
enhancement in their milk, Healthy Dairy will specify the feeding regime and nutrition 
requirements that producers must follow as part of their contract. 
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  The product will be first launched in California because it provides an ideal test 
market given its large population base and its consumers’ attitude towards healthy food 
products.  California consumers are believed to be highly responsive to public health 
campaigns and fad diets (e.g., California 5-a-Day Campaign) and are generally more health-
conscious compared to the rest of the American population (California Department of Health 
Services, 2004).  The focus on California is assumed to last two years, after which Healthy 
Dairy expects to expand its market to the rest of country in a systematic manner of growing 
market share through targeted penetration.  
  Since the adoption of new technology or product is dependent on need, it is assumed 
that only people who believe they are at risk of developing the three health conditions will be 
interested in Avert®.  This group does not include those who already suffer from the health 
condition since it is assumed that they will need to take their medication in order to benefit 
from their therapeutic effects instead of consuming Avert
® for its prophylactic effects.  It is 
assumed that the group consuming Avert
® for it prophylactic benefits will consist of people 
aged 25 to 84, who do not yet have any of the health conditions, based on the principle that 
early consumption of CLA-enhanced cheese is an effective way to prevent the onset of these 
health conditions. The population is divided in to ten-year cohorts (i.e., 25-34, 35-44, etc.).  
The risk associated with developing these health conditions varies among the different 
cohorts and generally, the risk increases as age increases.  Adoption of Avert
® is assumed to 
follow the Rogers adoption path that many other types of innovations, new ideas, products 
and practices.  The adoption path is based on the idea that innovative ideas, products, and 
practices are not adopted by all members in society at the same time.  
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females who do not have any cancer and who will purchase Avert
® as a preventative method.   
It is predicted that Healthy Dairy’s contribution to the market will reach about 10 percent of 
the consumers in the target market. 
  We have assumed that females and individuals earning an annual income of $75,000 
USD or more are more likely to purchase functional foods than males or individuals earning 
an annual income less than $75,000 USD (IFIC, 2005).  Also, even though people at risk of 
developing these health conditions are more likely to consume CLA-enhanced cheese, only a 
certain percentage of these people will actually purchase CLA-enhanced cheese.  
  We have also assumed that consumers have high brand loyalty and their degree of 
brand loyalty increases with income.  Therefore, it is assumed that once consumers switch to 
Avert
®, they will continue to be loyal to the brand for the duration of the analysis.  Another 
assumption is that the majority of households will purchase only one brand of cheese.  Since 
females are the main household purchasers of food and they are more likely to purchase 
Avert
®, it is assumed that Avert
® will be the cheese purchased for the household.   
  Importantly, it is assumed that the individuals in the target market are not the same 
Avert
® consumers every time.  Realistically, Healthy Dairy does not anticipate each 
individual in its target market to consume three servings of Avert
® a day.  However, Healthy 
Dairy is assuming that, collectively as a group, individuals in the target market will consume 
the daily recommended amount of Avert
® cheese in order to meet the target cheese 
consumption determined by Healthy Dairy (i.e., 0.28 pounds of Avert
® cheese per day). 
  Because of its contribution to health status improvement, Avert
®, is being presented 
as a competitor to pharmaceutical products that provide similar value propositions to 
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® is structured to reflect its real market 
competitors without losing sight of their potential to increase market share through strategic 
market penetration.  Therefore, Healthy Dairy plans to price Avert
® above traditional cheese 
but below the price of pharmaceutical products targeting the disease of interest of Healthy 
Dairy.  The following relationship is the basis for Avert
®’s pricing scheme: 
where P 0 A PPP ≤≤ P 0 is the traditional cheese price, PA is Avert
®’s price and PP is the 
weighted average price of leading pharmaceutical products for breast and prostate cancer – 
Tamoxifen and Casodex.  It is important to recognize that the benefits of Avert
® captured by 
this pricing method are underestimated.  Through consumption of Avert
®, which has no 
known medical side effects, consumers are preventing the onset of cancer without 
experiencing any of the unpleasant side effects of the pharmaceutical drugs.  Also, the costs 
stated for the pharmaceutical drug are the accounting costs (i.e., out of pocket costs) and are 
not the total economic costs associated with these drugs (e.g., the cost of loss of 
productivity).  Although Healthy Dairy recognizes the importance of the economic cost of 
the competing products, it consciously uses the out-of-pocket costs as the benchmark in 
pricing Avert
®. 
  Healthy Dairy will manufacture Avert
® from raw milk received by their contracted 
milk producers and distribute Avert
® cheese to its retail partners.  A premium of $0.05 per 
pound of milk will be paid to milk producers for milk that contains the specific level of CLA 
required by Healthy Dairy.  Otherwise no premium will be paid to producers, and instead the 
premium will be used to purchase CLA supplements that will be added to the cheese to 
ensure that the end product will contain the specific level of CLA. 
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® cheese and 
possibly from the sales of nonfat skim milk.  From 1998 to 2004, the average US retail price 
for 40 lb cheddar cheese (traditional cheese) was $1.37 per pound, assuming a 40 percent 
mark up factor (NASS, 1998- 2005).  Thus, a processor will typically sell traditional cheese 
for $0.833 per pound.  The premium received by processors is dependent on the processing 
costs especially the input costs (i.e., cost of CLA-enhanced milk).  
   Costs associated with the processing facility are from the purchases of raw milk from 
dairy producers, processing costs associated with CLA-enhanced cheese and possibly skim 
milk powder and transaction costs associated with developing contracts with producers.  As 
mentioned above, the cost of raw milk is highly dependent on its CLA content.  The cost of 
purchasing CLA supplements is part of the processor cost.  The cost of CLA supplement is 
determined by multiplying the CLA deficiency (the amount of CLA supplement required to 
meet the standard CLA amount per pound of milk) by the CLA supplement price.  The CLA 
supplement price is based on $0.05 multiplied by the ratio of CLA deficiency to the standard 
CLA amount.  
  Given that ten pounds of CLA-enhanced milk is needed to produce one pound of 
cheese.  Therefore, ten pounds of CLA-enhanced milk will cost processors more than $1.36 
to produce one pound of cheese.  Data from 1989 to 2004 estimates the weighted average 
manufacturing costs
6 for a Californian cheese processing facility to be $0.1726 per pound 
(Department of Food and Agriculture, 2004).  Included in this manufacturing cost are 
marketing costs.  As Healthy Dairy enters into the national market, intensive marketing 
campaigns are needed to attract more consumers.  Even though, Healthy Dairy is benefiting 
from economies of scale when processing the high volume of milk to satisfy the national 
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interest on capital investment is implicit in the manufacturing costs.  To simplify the 
modeling process, a Cobb Douglas production function (i.e., constant returns to scale) was 
assumed. 
  The production segment is based on individual dairy operation(s) in South Central 
Valley, who all share a common objective to maximize their profits by producing high 
valued CLA-enhanced milk.  Each one of the dairies is a representative of an average dairy 
operation in South Central Valley.  Based on historical data and industry predicted (Blayney, 
2002), the growth rate for dairy herds is 4.52 percent per annum.  This rate is assumed to 
prevail among the contract farms.    Given that the average annual cull rate for a dairy 
operation is 38 percent as suggested by Dr. M. Brouk from Kansas State University, this 
implies that the annual replacement rate for herd development is set at 42.52 percent.  
  Recall, Healthy Dairy stipulates that their dairy producers feed the dairy cows a 
“special diet” consisting of 55 percent forage, 43 percent corn and two percent linseed.  The 
amount of milk produced per cow is a function of the feed ration and the feed to milk 
efficiency which is a function of breed.  The average Californian cow produces 
approximately 68 pounds per day (i.e., approximately 24,000 pounds of milk per year) 
(Genske, 2005).  In general, a milking cow that produces 68 pounds of milk per day 
consumes approximately 50 pounds of feed per day (CANWEST DHI, 2005).
7  The feed-to-
milk efficiency for a cow possessing these production characteristics is within the range of 
1.232 to 1.408 pounds of milk per one pound of feed consumed (CANWEST DHI, 2005).   
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production:  (, ) Milk Productivity f CLAcontent genetics =  and 
.  Let milk composition, c, given by  (, Yield f milk productivity numberof cows = )
)
)
( c f CLAContent = , where milk composition (i.e., milk fat content) is negatively affected 
by CLA content.  Also, it is assumed that the CLA content cannot be predicted ex ante. CLA 
itself is influenced by genetics and diet.  (, CLAContent f genetics feed quality =  
  Total revenue generated by a dairy operation is equal to the revenue earned from milk 
production and selling culled cattle.  Expenses for a single dairy operation include the cost of 
replacing cattle to support herd development, feed costs, and other operating costs.   
  In figure 1, A Causal Loop Diagram (CLD) is used to illustrate the relationship and 
feedback structure of the Healthy Dairy’s supply chain.  The arrows in the diagrams 
represent the relationships between the system components and the signs above the arrow 
indicate the direction of the effect with respect to the cause (Carlevaro et al., 2004).   
 Results 
Along with the base scenario, two other alternative scenarios were analyzed.  Scenario 1, an 
internal scenario, presents a situation in which Healthy Dairy can control while Scenario 2, 
an external scenario, is outside of its control.  In Scenario 1, we assume that Healthy Dairy’s 
premium will decrease from 50 percent to 20 percent over the ten year period, in response to 
a demand price pressure exerted by competitors.  Since Healthy Dairy has positioned Avert
® 
as a premium product, purchasing rights based on their position the demand price pressure is 
expected to make Healthy Dairy unprofitable under this scenario. 
  Recall that under the base scenario, the daily recommended amount of Avert
® is 0.28 
pounds.  Under Scenario 2, we assume that individuals in the target market, collectively as a 
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®.  The target 
cheese consumption is expected to be smaller in Scenario 2 compared to the base scenario.   
Base Scenario  
The discounted revenue for Avert
® sales over the 10 years at 8 percent was $2.24 billion with 
a discounted cost of $1.57 billion.  The net present value (NPV) of Healthy Dairy’s profit 
stream over the 10 years was $665 million.  Producers supplying milk to Healthy Dairy 
realized a total discounted revenue of $1.39 billion over the period and cost of $910 million 
leading to a profit of almost $480 million over the ten years.   
  Figure 3 represents the average annual cheese price received by Healthy Dairy and 
the impact of these prices on their profit per pound of cheese and figure 4 represents the 
impact of milk prices paid by Healthy Dairy to its producers on the producers’ profits per 
pound of milk.  It is obvious from figure 3 that there is a strong positive correlation between 
Avert
® price and unit profit of cheese (correlation coefficient of 0.98).  Therefore, Healthy 
Dairy’s profits are very dependent on the price that they receive for Avert
® price.  We 
therefore explore the explanatory power of price on profit.  This will help determine the 
critical role of price for Healthy Dairy and its producers.  Using a single linear model, we 
estimated profit per pound of milk and cheese as a function of the price of milk and cheese.  
The results are presented in equation (1) and (2) respectively.  
      (1)  ()
1= 0.01583 + 0.17586  + 





2A = -0.68897 + 0.60005  + 




    (2) 
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where π1 represent producers’ profit per pound of milk, π2 represents Healthy Dairy’s profit 
per pound of Avert
® cheese, PMK represents price per pound of milk and PA represents price 
per pound of Avert
®. 
  In equation 1, the milk price is insignificant at the 5 percent significance level.  From 
the equation, a $1 increase in PMK will result in a $0.18 increase in π1.  In equation 2, PA is 
significant at the 5 percent significance level and it explains a $1 increase in PA will result in 
a $0.60 increase in π2.  The foregoing suggests that Healthy Dairy’s profit is more dependent 
upon the price of their product (i.e., Avert
®) than producer’s profit is on milk price. This may 
be explained by the fact that producers have alternative outlets for its CLA-enhanced milk, 
such as forfeiting their CLA milk premium and selling the milk on the traditional milk 
market; Healthy Dairy has designed its product and marketing strategy to one specific market 
– the CLA-enhanced food market.  Therefore, unlike producers, Healthy Dairy has a very 
limited number of alternative markets in which Avert
® could be sold.  Producers have the 
opportunity to focus on cost minimization, instead of price maximization as a strategy.  
Healthy Dairy, on the other hand, has focused all on its manufacturing and marketing efforts 
towards the success of Avert
® and has limited its opportunity to minimize costs without 
adversely affecting the value proposition of Avert
®.  Thus, Healthy Dairy’s profit strategy 
centers on its ability to maximize the price of Avert
®.   
Scenario 1 
In the base scenario, we have shown that price is a very significant variable in the 
profitability of Healthy Dairy.  With this in mind, Scenario 1 explains the effect of premium 
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percent over the ten year simulation period.  
  Producers’ profit decrease by 8.07 percent to a NPV of nearly $442 million compared 
to the base scenario (table 2).  Producers also experienced a 0.49 percent decrease in their 
revenue and a 40 percent decrease in their costs in comparison to base scenario parameters.  
Healthy Dairy’s profit decreased by 68.31 percent to a NPV of $211 million in comparison to 
the base scenario.  The NPV of Healthy Dairy’s revenue fell 20.63 percent from the base 
scenario but its cost slightly decreased by 0.43 percent.  Despite this significant decrease in 
profits, Healthy Dairy was able to earn positive profits under this scenario.  Interestingly, the 
producers are more profitable than Healthy Dairy under these market conditions.   
Scenario 2  
In Scenario 2, we assume that consumers are consuming two-thirds of the daily 
recommended intake.  However, Healthy Dairy is producing enough Avert
® to meet the daily 
recommended intake for the target market.  Therefore, there is an excess supply of Avert
® in 
the market.  We assume that Healthy Dairy will market the excess supply of Avert
® to the 
traditional cheese market.  Under this scenario, the NPV of processor’s profit decreased by 
44 percent to about $372 million while producers’ profit decreased by 7.50 percent to $444 
million (table 3).  During the ten year period, the total target Avert
® consumption decreased 
by 33.36 percent over the base scenario parameter. 
Summary of Results   
The analysis suggests that Healthy Dairy can be competitive in the functional food market if 
the company satisfies the proposed conditions.  The two main conditions are market size and 
price, with the latter being the most critical to the feasibility of Avert
®.  With respect to the 
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largest population possible and encouraging them to purchase Avert
®.  We suggest that 
Healthy Dairy must effectively manage variables within their control and minimize the 
adverse impacts of external variables.  To this end, we suggest that Healthy Dairy focuses on 
two principal areas of strategy: production and market relationship.  Specifically, it must 
ensure that it is operating as efficiently as possible within the cheese processing segment of 
the supply chain.   
  It is important for Healthy Dairy to enhance its market penetration activities through 
collaboration with cancer organizations.  For example, Healthy Dairy must work with 
American Cancer Society to educate the public and increase its awareness about the 
usefulness of functional foods such as Avert
® in combating cancer.  Simultaneously, Healthy 
Dairy must work with the Food and Drug Administration to secure a health claim for Avert
®.   
  Given the importance of pricing, Healthy Dairy must establish a price that will attract 
the largest group of consumers as well as generate sufficient revenue to more than cover the 
company’s costs.  To achieve this, Healthy Dairy prices Avert
® at a premium above the price 
of traditional cheese but below the price of pharmaceutical cancer drugs.  Healthy Dairy will 
target to the health-conscious consumers in its pricing, presentation, and marketing of 
Avert
®.  In addition to these pricing and marketing factors, Healthy Dairy’s success also 
depends on maintaining a high level of operational efficiency in its processing activities.  
Limitations and Suggestions for Further Research 
In this article, we researched three scenarios for this hypothetical firm. The scenario 
contained realistic market conditions in which we thought that the firm could achieve.  For 
simplicity and efficiency sakes, we omitted certain components of the supply chain (e.g., 
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price of Avert
®).  Another limitation of the model is that a Cobb-Douglas production 
function was assumed throughout the article.  The effects of this assumption could have been 
reflected in the absence of scale effects resulting from the changes in market size and 
productivity in the model.  The challenge of finding specific cost data on some of the cost 
items by location forced us to bundle cost into total operating cost at both stages in the 
Avert® production process, i.e., CLA-enhanced milk and CLA-enhanced cheese.   
We believe these constraints influenced the results by making them conservative.  For 
example, relaxing the constant return to scale assumption would enhance the profitability of 
the operation than was observed.  Also, unbundling costs would allow us to determine the 
principal cost effects on profitability besides feed costs at the production level and milk costs 
at the processing level.   
  Finally, we assumed that those consuming Avert
® achieved the results they expected, 
i.e., health status improvement.  Further research may relax this assumption and assess the 
profitability implications for post-marketing efficacy effects (Amanor-Boadu, 2005) for this 
functional food product.  Future research may investigate the feasibility of Avert
® for 
Healthy Dairy under different market conditions.  Since the Healthy Dairy’s profits are 
sensitive to pricing of Avert
® , a scenario determining the breakeven price for Healthy Dairy 
would be worth investigating.   
Conclusion 
The purpose of this research was to determine the economic feasibility of introducing Avert
® 
into a target market comprising of consumers interested in preventing the onset of certain 
types of cancer – breast and prostate.  It also investigated the alternative scenarios that could 
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feasibility of the introducing Avert
®.  The results allowed us to develop some strategic 
options for Healthy Dairy to minimize the adverse impacts and enhance the positive impacts 
of the alternate scenarios.  
  A system dynamic modeling approach provided an effective tool to effectively 
conduct scenario analysis for Healthy Dairy’s imitative to introduce Avert
® to market.  It 
allows the modeling of alternative assumptions and capturing of the results for comparisons 
and analyses.  More importantly, it allows management to understand the direct, indirect and 
seemingly unrelated relationships among the different factors that affect performance.    
  The results suggest that it is feasible to introduce Avert
® into the market provided 
Healthy Dairy develops a production and marketing system that reflects the assumptions we 
presented.  The prevent value of total chain profits – processor and producers – under the 
base scenario were estimated at $1.1 billion.  To test the robustness of the feasibility of 
Avert
® in the market, we evaluated the profits under two alternative scenarios – a decrease in 
premium price and a decrease in quantity of Avert
® consumed by individuals in the target 
market.  The results showed that the product was robust under these market conditions.  
However, Healthy Dairy was the least profitable when the premium on Avert
®’s price drops 
dropped to 20 percent.  This suggests that the market feasibility of this particular product is 
extremely sensitive to market prices. Thus, Healthy Dairy needs to ensure that it can extract 
high enough premiums from the market if it is going to differentiate itself enough from the 
commodity market to secure a profitable return on its operations.  Given the importance of 
the premium for Avert
® on Healthy Dairy’s profits, it is strongly recommended for future 
research to identify the premium that leads to negative profits for Healthy Dairy. 
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Figure 2.Casual loop diagram of  Healthy Dairy's supply chain 
  35Table 1. Discounted Economic Results of Base Scenario 
 







Revenue                                   1,390
 
 Cost                                      910
 




 Cost  1,570
 Profit  665
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Profit/ Lb of Cheese Avert Price  
Figure 4: Processor’s profit per pound of cheese produced 
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Table 2. Discounted Economic Results of Scenario 1 
 










Revenue                                  1,384
 
-0.49%
 Cost                                     943 3.51%
 





 Cost  1,563 -0.43% 




  39Table 3. Discounted Economic Results of Scenario 2 
 









Revenue                                  1,380
 
-0.73%
 Cost                                     936 2.84%
 




 Cost  1,560 -0.64% 
 Profit  372 -44.0% 
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1 Adipose tissue  is the connective tissue in ruminants that stores fat cells  
2 Pulmonary tumor burden refers to the size of the tumor or number of cancer cells present in 
the lung. 
3 Uncontrolled cell proliferation is a key sign of cancer in the body. 
4 In the federal milk order program, producers are paid a price for each pound of milk 
component marketed as well as the producer priced differential (weighted average value of 
the effective Class I and Class II differentials.   In California, minimum hundredweight price 
is established based on the milk components. 
5 Cheese sales from Wal-Mart are excluded from the Total Cheese sales. 
6 Weighted average manufacturing costs include processing labor, non-labor processing, 
packaging, other ingredients, general and administrative and return on investment costs. 
7 A cow that consumes 50 pounds of total dry matter intake produces 61.6 to 70.4 pounds of 
milk per day  
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